NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

Specifically, optic nerve lesions will make it easier to fulfill the dissemination in space (DIS) principle, a pivotal concept for delivering a diagnosis of MS in patients with CIS, said Calabresi ...

What is Glaucoma? Glaucoma is an eye disease caused by increased pressure in the eye, which can damage the optic nerve and ...

For the past 20 years treatment with high-dose corticosteroids and optic nerve decompression have been favored. However, recent evidence has raised questions regarding the value of these treatments.

Glaucoma is the second leading cause of blindness in the U.S.A primary screening tool for glaucoma is measurement of IOP. The ...

Glaucoma is characterized by increased intraocular pressure in many but not all cases. Some people with glaucoma have normal intraocular pressure but poor circulation, which can damage the optic ...

Researchers in Gisborne are helping develop a new MRI scan method, which they say can detect subtle brain lesions in multiple ...

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company") is pleased to announce new preclinical results ...

Using the CatWalk XT system, researchers assessed ExoPTEN’s effect on the animals’ ability to walk. All animals (100%) in the higher-dose group demonstrated measurable gait recovery, in contrast to ...

Kevin Choi uses AI to detect critical diseases early through retinal scans. He said AI helps in screening, but it won't ...

Dilated pupils in cats can be a sign of iris atrophy or a more serious underlying condition. Here’s how to know when to seek ...